In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Switching among biologic therapies is common practice in ... or loss of efficacy or adverse events associated with initial anti-TNF therapy. However, patients receiving TNF antagonist therapy ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of ...

Several important and very large biologic therapy areas are facing loss ... and anti-tumor Necrosis Factors monoclonal antibodies (anti-TNF mAbs). • A non-original version of filgrastim, an ...

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...